Anastos K, Kovacs A, Kalish L, Hessol N, Delapenha R, Burns D, Weiser B, Cohen M, Meyer W, Bremer J, Melnick S; Conference on Retroviruses and Opportunistic Infections.

Program Abstr 5th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 5th 1998 Chic Ill. 1998 Feb 1-5; 5th: 117 (abstract no. 207).

Montefiore Medical Center, Bronx, NY.

Objective: To determine factors associated with survival in HIV infected (HIV+) women. Methods: We analyzed data from WIHS, a prospective study of 2058 HIV+ and 567 HIV uninfected women recruited in five US cities from 10/94- 10/95. Clinical, virologic and immunologic evaluations were performed every six months. Notification of participant death was obtained from participant friends, relatives, and medical providers. Adjusted associations between covariates and survival were assessed with proportiond hazards models. Results: There were 242 deaths in the l890 HIV+ women with at least some follow-up information (median 22.8 months). The Kaplan-Meier estimates of death within one and two years of follow-up were 6.2% and 13.7%. In a multivariate proportional hazards model the relative hazards of death (RH) were 2.87, 2.02, 3.79 and 7.10 respectively for RNA 4-20K, 20-100K, 100-500K, and greater than or equal to 500K relative to RNA less than 4K (p less than .0001). RH=1.01,2.92 and 8.09 respectively for CD4 200-499, 50199 and less than 50 relative to CD4 greater than or equal to 500 (p less than .000l). RH=2.04 for a self-reported prior AIDS defining condition (p less than .0001). Compared to women with CD4 greater than or equal to 200 and RNA less than 20K (18 mo. mortality 2.7%) women with CD4 less than 50 and RNA greater than or equal to 500K (18 mo. mortality 71.5%) had a RH of 35.17. There was a trend toward poorer survival in older participants (p=.16). Survival was not associated with race/ethnicity or route of HIV exposure. Conclusion: Women with CD4 counts less than 50 and RNA greater than or equal to 500K had the greatest risk of death.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Proportional Hazards Models
• Prospective Studies
• RNA
• RNA, Viral
• Survival
• Survival Analysis

Other ID:

• 98929133

UI: 102235786

From Meeting Abstracts